## Joseph N Contessa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2111377/publications.pdf

Version: 2024-02-01

42 papers 1,752 citations

430874 18 h-index 315739 38 g-index

42 all docs 42 docs citations

times ranked

42

2990 citing authors

#	Article	IF	CITATIONS
1	Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 2022, 526, 346-351.	7.2	10
2	Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100949.	1.2	1
3	Aberrant Cellular Glycosylation May Increase the Ability of Influenza Viruses to Escape Host Immune Responses through Modification of the Viral Glycome. MBio, 2022, 13, e0298321.	4.1	4
4	Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer. Journal of the National Cancer Institute, 2021, 113, 652-653.	6.3	0
5	The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress. Science Advances, 2021, 7, .	10.3	17
6	STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications, 2021, 12, 2327.	12.8	78
7	Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. , 2021, 9, e002684.		8
8	Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiotherapy and Oncology, 2020, 142, 168-174.	0.6	29
9	UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. Translational Oncology, 2020, 13, 100834.	3.7	12
10	Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clinical Cancer Research, 2019, 25, 784-795.	7.0	32
11	Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2019, 18, 2124-2134.	4.1	9
12	Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. Anticancer Research, 2019, 39, 2911-2918.	1.1	8
13	Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	14
14	Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1091-1098.	0.8	89
15	Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clinical and Translational Radiation Oncology, 2019, 15, 46-52.	1.7	9
16	Targeting STT3Aâ€oligosaccharyltransferase with NGIâ€1 causes herpes simplex virus 1 dysfunction. FASEB Journal, 2019, 33, 6801-6812.	0.5	12
17	MPDU1 regulates CEACAM1 and cell adhesion in vitro and in vivo. Glycoconjugate Journal, 2018, 35, 265-274.	2.7	1
18	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	10.7	108

#	Article	IF	CITATIONS
19	Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncology, 2018, 79, 64-70.	1.5	42
20	Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. Journal of Neuro-Oncology, 2018, 136, 289-298.	2.9	4
21	Editing N-Glycan Site Occupancy with Small-Molecule Oligosaccharyltransferase Inhibitors. Cell Chemical Biology, 2018, 25, 1231-1241.e4.	5.2	31
22	CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2018, 8, 95.	2.8	36
23	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.9	47
24	Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial Journal of Clinical Oncology, 2018, 36, e14046-e14046.	1.6	7
25	PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases Journal of Clinical Oncology, 2018, 36, e24116-e24116.	1.6	3
26	A multi species evaluation of the radiation dosimetry of [ 11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nuclear Medicine and Biology, 2017, 47, 56-61.	0.6	8
27	Management of Brain Metastases in Tyrosine Kinase Inhibitor–NaÃ⁻ve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372
28	The prognostic value of extranodal extension in human papillomavirusâ€associated oropharyngeal squamous cell carcinoma. Cancer, 2017, 123, 2762-2772.	4.1	105
29	Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy. JAMA Oncology, 2017, 3, 1107.	7.1	32
30	Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy and Oncology, 2017, 125, 258-265.	0.6	3
31	Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. Journal of Neuro-Oncology, 2017, 135, 403-411.	2.9	30
32	A Small-Molecule Oligosaccharyltransferase Inhibitor with Pan-flaviviral Activity. Cell Reports, 2017, 21, 3032-3039.	6.4	65
33	CDKN2A copy number loss in HPV- and HPV+ head and neck cancer to indicate poor prognosis: An integrated genomic and clinical TCGA analysis Journal of Clinical Oncology, 2017, 35, 6060-6060.	1.6	1
34	Reply to M.S. Copur et al and to M.C. Chamberlain. Journal of Clinical Oncology, 2016, 34, 2316-2317.	1.6	0
35	Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nature Chemical Biology, 2016, 12, 1023-1030.	8.0	88
36	Extended Survival and Prognostic Factors for Patients With <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. Journal of Clinical Oncology, 2016, 34, 123-129.	1.6	284

#	Article	IF	CITATION
37	Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2016, 4, 97-106.	0.2	1
38	Mannose Phosphate Isomerase Regulates Fibroblast Growth Factor Receptor Family Signaling and Glioma Radiosensitivity. PLoS ONE, 2014, 9, e110345.	2.5	14
39	High-throughput Screening Identifies Aclacinomycin as a Radiosensitizer of EGFR-Mutant Non-Small Cell Lung Cancer. Translational Oncology, 2013, 6, 382-391.	3.7	14
40	Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain. Neoplasia, 2013, 15, 1347-1353.	5.3	43
41	Molecular Imaging of <i>N</i> -linked Glycosylation Suggests Glycan Biosynthesis Is a Novel Target for Cancer Therapy. Clinical Cancer Research, 2010, 16, 3205-3214.	7.0	79
42	Targeted radiation for melanoma: Alpha therapy prepares for a beta test. Cancer Biology and Therapy, 2006, 5, 118-119.	3.4	2